LT3466955T - Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas - Google Patents

Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas

Info

Publication number: LT3466955T
Authority: LT; Lithuania
Prior art keywords: pyridine; oxaszol; iraq4; thiazol; inhibitors
Prior art date: 2014-01-13

Application number

LTEP18190333.7T

Other languages

English (en)

Inventor

Venkateshwar GUMMADI

Susanta Samajdar

Original Assignee

Aurigene Discovery Technologies Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-13

Filing date

2015-01-12

Publication date

2021-02-25

2015-01-12 Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited

2021-02-25 Publication of LT3466955T publication Critical patent/LT3466955T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)

LTEP18190333.7T 2014-01-13 2015-01-12 Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas LT3466955T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN158CH2014		2014-01-13
IN3000CH2014		2014-06-20

Publications (1)

Publication Number	Publication Date
LT3466955T true LT3466955T (lt)	2021-02-25

Family

ID=53523587

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP18190333.7T LT3466955T (lt)	2014-01-13	2015-01-12	Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
LTEP20211096.1T LT3805233T (lt)	2014-01-13	2015-01-12	N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
LTEP15735499.4T LT3094329T (lt)	2014-01-13	2015-01-12	Bicikliniai heterociklilo dariniai kaip irak4 inhibitoriai

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
LTEP20211096.1T LT3805233T (lt)	2014-01-13	2015-01-12	N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
LTEP15735499.4T LT3094329T (lt)	2014-01-13	2015-01-12	Bicikliniai heterociklilo dariniai kaip irak4 inhibitoriai

Country Status (31)

Country	Link
US (8)	US9732095B2 (lt)
EP (4)	EP4353324A3 (lt)
JP (7)	JP6479850B2 (lt)
KR (4)	KR102574390B1 (lt)
CN (2)	CN106456619B (lt)
AU (6)	AU2015205374B2 (lt)
BR (1)	BR112016016158B1 (lt)
CA (1)	CA2935887A1 (lt)
CU (1)	CU24389B1 (lt)
CY (2)	CY1121433T1 (lt)
DK (3)	DK3805233T3 (lt)
EA (2)	EA038748B1 (lt)
ES (3)	ES2846678T3 (lt)
FI (1)	FI3805233T3 (lt)
HR (3)	HRP20240489T1 (lt)
HU (3)	HUE041926T2 (lt)
IL (7)	IL311677B2 (lt)
LT (3)	LT3466955T (lt)
MX (1)	MX359909B (lt)
MY (1)	MY197116A (lt)
NZ (2)	NZ760657A (lt)
PH (2)	PH12016501344A1 (lt)
PL (3)	PL3466955T3 (lt)
PT (3)	PT3805233T (lt)
RS (3)	RS58024B1 (lt)
SG (2)	SG11201605486WA (lt)
SI (3)	SI3466955T1 (lt)
SM (3)	SMT202400142T1 (lt)
TR (1)	TR201815683T4 (lt)
WO (1)	WO2015104688A1 (lt)
ZA (4)	ZA202007275B (lt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
BR112016015983A2 (pt)	2014-01-10	2017-08-08	Aurigene Discovery Tech Ltd	Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
SMT202400142T1 (it) *	2014-01-13	2024-05-14	Aurigene Oncology Ltd	Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
CN108024971A (zh) *	2015-07-15	2018-05-11	奥列基因发现技术有限公司	作为irak-4抑制剂的取代的氮杂化合物
ES2811136T3 (es)	2015-08-04	2021-03-10	Rigel Pharmaceuticals Inc	Compuestos de benzazol y métodos para obtener y usar los compuestos
JP6947743B2 (ja)	2016-03-03	2021-10-13	バイエル・ファルマ・アクティエンゲゼルシャフト	新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
TWI733982B (zh)	2017-02-16	2021-07-21	美商基利科學股份有限公司	吡咯并[1,2-b]嗒衍生物
CN120267671A (zh)	2017-03-31	2025-07-08	奥锐金肿瘤有限公司	用于治疗血液病的化合物和组合物
JP7366031B2 (ja)	2017-09-22	2023-10-20	カイメラセラピューティクス，インコーポレイテッド	タンパク質分解剤およびそれらの使用
WO2019060693A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	CRBN LIGANDS AND USES THEREOF
MX2020003666A (es) *	2017-10-31	2020-08-03	Curis Inc	Compuestos y composiciones para el tratamiento de trastornos hematologicos.
US11065231B2 (en)	2017-11-17	2021-07-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
EP3737666A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US11512080B2 (en)	2018-01-12	2022-11-29	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
EP3305786A3 (de)	2018-01-22	2018-07-25	Bayer CropScience Aktiengesellschaft	Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CA3090275A1 (en)	2018-02-14	2019-08-22	Dana-Farber Cancer Institute, Inc.	Irak degraders and uses thereof
EP3817822A4 (en)	2018-07-06	2022-07-27	Kymera Therapeutics, Inc.	PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Tricyclic crbn ligands and uses thereof
TWI721483B (zh)	2018-07-13	2021-03-11	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
CA3224985C (en)	2018-07-31	2025-11-18	Loxo Oncology, Inc.	SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP7623943B2 (ja)	2018-11-30	2025-01-29	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
US20220089592A1 (en) *	2019-01-18	2022-03-24	Biogen Ma Inc.	Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
BR112021026517A2 (pt)	2019-06-28	2022-05-10	Kymera Therapeutics Inc	Degradadores de irak e usos dos mesmos
WO2021004533A1 (zh) *	2019-07-10	2021-01-14	南京明德新药研发有限公司	作为irak4和btk多靶点抑制剂的噁唑类化合物
WO2021011868A1 (en)	2019-07-17	2021-01-21	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
ES2961950T3 (es)	2019-07-18	2024-03-14	Bristol Myers Squibb Co	Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4
EP3999512B1 (en)	2019-07-18	2023-08-23	Bristol-Myers Squibb Company	Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors
JP7573596B2 (ja) *	2019-07-23	2024-10-25	ブリストル－マイヤーズスクイブカンパニー	Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
JP7682154B2 (ja)	2019-08-06	2025-05-23	ブリストル－マイヤーズスクイブカンパニー	Ｉｒａｋ４阻害剤として有用な二環ヘテロ環式化合物
EP3772513A1 (en) *	2019-08-09	2021-02-10	C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening	Shp2 inhibitors
EP4013758B1 (en)	2019-08-13	2025-12-24	Bristol-Myers Squibb Company	Bicyclic heteroaryl compounds useful as irak4 inhibitors
AU2020360000B2 (en)	2019-10-02	2023-04-20	Kainos Medicine, Inc.	N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
EP4072591A4 (en)	2019-12-10	2024-06-05	Kymera Therapeutics, Inc.	IRAQ DEGRADER AND USES THEREOF
WO2021127283A2 (en)	2019-12-17	2021-06-24	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
JP2023509366A (ja)	2019-12-17	2023-03-08	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
US12391702B2 (en)	2020-02-03	2025-08-19	Bristol-Myers Squibb Company	Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
CA3177852A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
WO2021204589A1 (en)	2020-04-07	2021-10-14	Bayer Aktiengesellschaft	Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
WO2021222366A1 (en) *	2020-04-28	2021-11-04	Kymera Therapeutics, Inc.	Irak inhibitors and uses thereof
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
KR20230048358A (ko) *	2020-08-03	2023-04-11	쿠리스 인코퍼레이션	질환 및 장애를 치료하기 위한 조성물 및 방법
EP4237423B1 (en)	2020-11-02	2024-12-11	Boehringer Ingelheim International GmbH	Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
WO2022108996A1 (en) *	2020-11-18	2022-05-27	Curis, Inc.	Methods of treating diseases and disorders
EP4269409A4 (en) *	2020-12-25	2024-12-11	Medshine Discovery Inc.	AMIDE-OXAZOLE COMPOUND
WO2022147465A1 (en)	2020-12-30	2022-07-07	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
TW202245788A (zh)	2021-02-15	2022-12-01	美商凱麥拉醫療公司	Irak4降解劑及其用途
CN116867494A (zh)	2021-02-15	2023-10-10	凯麦拉医疗公司	Irak4降解剂和其用途
US12178821B2 (en)	2021-04-08	2024-12-31	Curis, Inc.	Combination therapies for the treatment of cancer
AU2022271290A1 (en)	2021-05-07	2023-11-23	Kymera Therapeutics, Inc.	Cdk2 degraders and uses thereof
TW202328150A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
EP4422635A4 (en)	2021-10-29	2025-11-26	Kymera Therapeutics Inc	IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
TWI890016B (zh)	2021-12-23	2025-07-11	大陸商杭州多域生物技術有限公司	一種五員并六員化合物、製備方法、藥物組成物和應用
TW202330546A (zh) *	2021-12-31	2023-08-01	香港商愛科諾生物醫藥(香港)有限公司	具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用
IL314437A (en)	2022-01-31	2024-09-01	Kymera Therapeutics Inc	IRAK joints and their uses
US12384775B2 (en)	2022-03-23	2025-08-12	Rigel Pharmaceuticals, Inc.	Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors
JP2025534698A (ja) *	2022-10-13	2025-10-17	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ４デグレーダーの塩の形態
WO2024092011A1 (en) *	2022-10-25	2024-05-02	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
WO2025130871A1 (zh) *	2023-12-20	2025-06-26	爱科诺生物医药(香港)有限公司	具有irak4和flt3蛋白双重降解活性的化合物，包含其的药物组合物，及其应用
WO2025208000A1 (en) *	2024-03-29	2025-10-02	Curis, Inc.	Methods of treating cancer in patients with altered protein expression
WO2026005536A1 (ko) *	2024-06-28	2026-01-02	주식회사 대웅제약	신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물
CN119119080A (zh) *	2024-09-06	2024-12-13	上海信诺维生物医药有限公司	一种irak4的蛋白降解剂

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2102367T3 (es)	1990-05-18	1997-08-01	Hoechst Ag	Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
DE10023486C1 (de)	2000-05-09	2002-03-14	Schering Ag	Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
WO2004063151A2 (en) *	2003-01-03	2004-07-29	Bristol-Myers Squibb Company	Novel tyrosine kinase inhibitors
US7651469B2 (en)	2003-04-25	2010-01-26	Cook Incorporated	Low friction coated marked wire guide for over the wire insertion of a catheter
ES2350837T3 (es)	2003-05-01	2011-01-27	Bristol-Myers Squibb Company	Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas.
ATE556067T1 (de)	2003-05-20	2012-05-15	Ajinomoto Kk	Modulatoren des vanilloid rezeptors
EP1628661A2 (en)	2003-06-05	2006-03-01	Vertex Pharmaceuticals Incorporated	Modulators of vr1 receptor
EP1493795A1 (de)	2003-07-04	2005-01-05	Collano AG	Klebstoffzusammensetzung
WO2005032493A2 (en)	2003-10-07	2005-04-14	Renovis, Inc.	Amide compounds as ion channel ligands and uses thereof
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
MXPA06012104A (es)	2004-04-22	2007-01-25	Bayer Cropscience Lp	Metodo y composicion para controlar malas hierbas.
US7906533B2 (en)	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655297A1 (en)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
TW200628159A (en)	2004-11-10	2006-08-16	Synta Pharmaceuticals Corp	IL-12 modulatory compounds
US7902356B2 (en)	2004-12-17	2011-03-08	Eli Lilly And Company	Thiazolopyridinone derivates as MCH receptor antagonists
CN101072775A (zh)	2004-12-17	2007-11-14	伊莱利利公司	新的mch受体拮抗剂
EP1674467A1 (en)	2004-12-22	2006-06-28	4Sc Ag	2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
AU2007215247B2 (en)	2006-02-10	2012-12-13	Transtech Pharma, Llc	Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
GB0606429D0 (en)	2006-03-30	2006-05-10	Novartis Ag	Organic compounds
WO2007117465A2 (en)	2006-03-31	2007-10-18	Abbott Laboratories	Indazole compounds
WO2007121154A2 (en)	2006-04-11	2007-10-25	Janssen Pharmaceutica, N.V.	Substituted benzothiazole kinase inhibitors
RU2459821C2 (ru) *	2006-09-07	2012-08-27	Байоджен Айдек Ма Инк.	Модуляторы киназы, ассоциированной с рецептором интерлейкина-1
AU2007292924A1 (en) *	2006-09-07	2008-03-13	Biogen Idec Ma Inc.	IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008061109A2 (en)	2006-11-15	2008-05-22	Forest Laboratories Holdings Limited	Indazole derivatives useful as melanin concentrating receptor ligands
WO2008073825A1 (en)	2006-12-08	2008-06-19	Exelixis, Inc.	Lxr and fxr modulators
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
AR066958A1 (es)	2007-06-14	2009-09-23	Schering Corp	Imidazopirazinas como inhibidores de proteina quinasa
US20090069288A1 (en)	2007-07-16	2009-03-12	Breinlinger Eric C	Novel therapeutic compounds
CA2690619A1 (en)	2007-07-16	2009-01-22	Abbott Laboratories	Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
BRPI0814975A2 (pt)	2007-08-08	2015-02-03	Merck Serono Sa	Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla
NZ587039A (en)	2008-02-13	2013-01-25	Gilead Connecticut Inc	6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
EP2311842A3 (en)	2008-06-24	2011-07-13	Takeda Pharmaceutical Company Limited	PI3K/M TOR inhibitors
CA2743609A1 (en)	2008-11-19	2010-05-27	Schering Corporation	Inhibitors of diacylglycerol acyltransferase
EP2379564A1 (en) *	2008-12-19	2011-10-26	Schering Corporation	Bicyclic heterocyclic derivatives and methods of use thereof
EP2393781B1 (en)	2008-12-23	2014-03-12	F. Hoffmann-La Roche AG	Dihydropyridone ureas as p2x7 modulators
EP2440058A4 (en)	2009-06-12	2012-11-21	Dana Farber Cancer Inst Inc	MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
BR112012003661A2 (pt)	2009-08-19	2017-04-25	Ambit Biosciences Corp	"compostos de biarila e métodos de uso dos mesmos."
JP2012254939A (ja)	2009-10-07	2012-12-27	Astellas Pharma Inc	オキサゾール化合物
JP5819305B2 (ja)	2009-10-13	2015-11-24	リガンド・ファーマシューティカルズ・インコーポレイテッド	造血成長因子模倣小分子化合物およびそれらの使用
JP2013525370A (ja)	2010-04-22	2013-06-20	ヤンセンファーマシューティカエヌ．ベー．	ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
EP2563358A4 (en)	2010-04-30	2013-09-25	Merck Sharp & Dohme	INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
HRP20171176T1 (hr)	2010-06-24	2017-10-06	Chemocentryx, Inc.	C5ar antagonisti
CN102985426B (zh)	2010-07-13	2015-10-07	弗·哈夫曼-拉罗切有限公司	作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
HUE037860T2 (hu)	2010-11-19	2018-09-28	Ligand Pharm Inc	Heterociklusos aminok és alkalmazásuk
WO2012084704A1 (en)	2010-12-20	2012-06-28	Merck Serono S.A.	Indazolyl triazole derivatives as irak inhibitors
WO2012142125A2 (en)	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013042137A1 (en) *	2011-09-19	2013-03-28	Aurigene Discovery Technologies Limited	Bicyclic heterocycles as irak4 inhibitors
MY167575A (en)	2011-10-14	2018-09-20	Ambit Biosciences Corp	Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
RU2014120166A (ru)	2011-10-20	2015-11-27	ГЛЭКСОСМИТКЛАЙН ЭлЭлСи	Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
US9221809B2 (en) *	2011-10-31	2015-12-29	Merck Sharp & Dohme Corp.	Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
GB201119401D0 (en)	2011-11-10	2011-12-21	Ucb Pharma Sa	Therapeutic agents
KR101385603B1 (ko)	2012-05-17	2014-04-21	한국원자력의학원	벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en)	2012-06-29	2014-01-03	Hanmi Pharm. Co., Ltd.	Fused pyrimidine derivatives having inhibitory activity on fms kinases
HK1210696A1 (en)	2012-07-11	2016-05-06	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
JP6372666B2 (ja)	2012-11-03	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	サイトメガロウイルスの阻害剤
US9168257B2 (en)	2013-05-22	2015-10-27	Children's Hospital Medical Center	Combination therapy for MDS
TWI652014B (zh)	2013-09-13	2019-03-01	美商艾佛艾姆希公司	雜環取代之雙環唑殺蟲劑
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
BR112016015983A2 (pt)	2014-01-10	2017-08-08	Aurigene Discovery Tech Ltd	Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
SMT202400142T1 (it)	2014-01-13	2024-05-14	Aurigene Oncology Ltd	Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
JP6532474B2 (ja)	2014-02-06	2019-06-19	アッヴィ・インコーポレイテッド	６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用
KR20170016500A (ko)	2014-06-20	2017-02-13	오리진 디스커버리 테크놀로지스 리미티드	Irak4 저해제로서의 치환된 인다졸 화합물
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh)	2015-04-30	2017-01-16	拜耳製藥公司	Ｉｒａｋ４抑制劑組合
AU2016293441A1 (en)	2015-07-15	2018-02-01	Aurigene Discovery Technologies Limited	Indazole and azaindazole compounds as IRAK-4 inhibitors
CN108024971A (zh)	2015-07-15	2018-05-11	奥列基因发现技术有限公司	作为irak-4抑制剂的取代的氮杂化合物
ES2811136T3 (es)	2015-08-04	2021-03-10	Rigel Pharmaceuticals Inc	Compuestos de benzazol y métodos para obtener y usar los compuestos
US20170035881A1 (en)	2015-10-19	2017-02-09	Acerta Pharma B.V.	Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
US20210292843A1 (en)	2016-10-28	2021-09-23	Children's Hospital Medical Center	Treatment of diseases associated with activated irak
CN120267671A (zh)	2017-03-31	2025-07-08	奥锐金肿瘤有限公司	用于治疗血液病的化合物和组合物
MX2020003666A (es)	2017-10-31	2020-08-03	Curis Inc	Compuestos y composiciones para el tratamiento de trastornos hematologicos.
JP7623943B2 (ja)	2018-11-30	2025-01-29	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
BR112021026517A2 (pt)	2019-06-28	2022-05-10	Kymera Therapeutics Inc	Degradadores de irak e usos dos mesmos
KR20230048358A (ko)	2020-08-03	2023-04-11	쿠리스 인코퍼레이션	질환 및 장애를 치료하기 위한 조성물 및 방법
WO2022108996A1 (en)	2020-11-18	2022-05-27	Curis, Inc.	Methods of treating diseases and disorders
US12178821B2 (en)	2021-04-08	2024-12-31	Curis, Inc.	Combination therapies for the treatment of cancer
IL316793A (en)	2022-05-11	2025-01-01	Curis Inc	Treating diseases and disorders with compounds that modify IRAK4
WO2024249837A1 (en)	2023-06-01	2024-12-05	Curis, Inc.	Methods of treating cancer in bcl2 inhibitor naive subjects
CN121398817A (zh)	2023-06-01	2026-01-23	柯里斯公司	治疗具有先前免疫检查点抑制剂暴露的受试者的癌症的方法

2015
- 2015-01-12 SM SM20240142T patent/SMT202400142T1/it unknown
- 2015-01-12 DK DK20211096.1T patent/DK3805233T3/da active
- 2015-01-12 IL IL311677A patent/IL311677B2/en unknown
- 2015-01-12 HR HRP20240489TT patent/HRP20240489T1/hr unknown
- 2015-01-12 HU HUE15735499A patent/HUE041926T2/hu unknown
- 2015-01-12 CA CA2935887A patent/CA2935887A1/en active Pending
- 2015-01-12 SG SG11201605486WA patent/SG11201605486WA/en unknown
- 2015-01-12 KR KR1020227014075A patent/KR102574390B1/ko active Active
- 2015-01-12 SM SM20180680T patent/SMT201800680T1/it unknown
- 2015-01-12 DK DK18190333.7T patent/DK3466955T3/da active
- 2015-01-12 ES ES18190333T patent/ES2846678T3/es active Active
- 2015-01-12 HU HUE20211096A patent/HUE066261T2/hu unknown
- 2015-01-12 LT LTEP18190333.7T patent/LT3466955T/lt unknown
- 2015-01-12 SM SM20210063T patent/SMT202100063T1/it unknown
- 2015-01-12 KR KR1020257009008A patent/KR20250049413A/ko active Pending
- 2015-01-12 EP EP23214923.7A patent/EP4353324A3/en active Pending
- 2015-01-12 IL IL284952A patent/IL284952B/en unknown
- 2015-01-12 TR TR2018/15683T patent/TR201815683T4/tr unknown
- 2015-01-12 NZ NZ760657A patent/NZ760657A/en unknown
- 2015-01-12 IL IL294895A patent/IL294895B2/en unknown
- 2015-01-12 HU HUE18190333A patent/HUE052252T2/hu unknown
- 2015-01-12 HR HRP20181795TT patent/HRP20181795T1/hr unknown
- 2015-01-12 NZ NZ722019A patent/NZ722019A/en unknown
- 2015-01-12 MX MX2016009013A patent/MX359909B/es active IP Right Grant
- 2015-01-12 EP EP18190333.7A patent/EP3466955B1/en active Active
- 2015-01-12 ES ES15735499.4T patent/ES2692852T3/es active Active
- 2015-01-12 IL IL317922A patent/IL317922A/en unknown
- 2015-01-12 RS RS20181355A patent/RS58024B1/sr unknown
- 2015-01-12 EA EA201891917A patent/EA038748B1/ru unknown
- 2015-01-12 PT PT202110961T patent/PT3805233T/pt unknown
- 2015-01-12 IL IL302878A patent/IL302878B2/en unknown
- 2015-01-12 BR BR112016016158-0A patent/BR112016016158B1/pt active IP Right Grant
- 2015-01-12 SG SG10201811204RA patent/SG10201811204RA/en unknown
- 2015-01-12 EP EP15735499.4A patent/EP3094329B1/en active Active
- 2015-01-12 CN CN201580013752.4A patent/CN106456619B/zh active Active
- 2015-01-12 AU AU2015205374A patent/AU2015205374B2/en active Active
- 2015-01-12 DK DK15735499.4T patent/DK3094329T3/en active
- 2015-01-12 KR KR1020237029626A patent/KR102785576B1/ko active Active
- 2015-01-12 PL PL18190333T patent/PL3466955T3/pl unknown
- 2015-01-12 EP EP20211096.1A patent/EP3805233B1/en active Active
- 2015-01-12 RS RS20210039A patent/RS61448B1/sr unknown
- 2015-01-12 LT LTEP20211096.1T patent/LT3805233T/lt unknown
- 2015-01-12 FI FIEP20211096.1T patent/FI3805233T3/fi active
- 2015-01-12 PL PL15735499T patent/PL3094329T3/pl unknown
- 2015-01-12 KR KR1020167021713A patent/KR102392684B1/ko active Active
- 2015-01-12 SI SI201531483T patent/SI3466955T1/sl unknown
- 2015-01-12 LT LTEP15735499.4T patent/LT3094329T/lt unknown
- 2015-01-12 SI SI201530477T patent/SI3094329T1/sl unknown
- 2015-01-12 ES ES20211096T patent/ES2975436T3/es active Active
- 2015-01-12 CN CN202010147212.8A patent/CN111362966B/zh active Active
- 2015-01-12 WO PCT/IB2015/050217 patent/WO2015104688A1/en not_active Ceased
- 2015-01-12 CU CU2016000111A patent/CU24389B1/es unknown
- 2015-01-12 PT PT15735499T patent/PT3094329T/pt unknown
- 2015-01-12 PT PT181903337T patent/PT3466955T/pt unknown
- 2015-01-12 PL PL20211096.1T patent/PL3805233T3/pl unknown
- 2015-01-12 SI SI201532008T patent/SI3805233T1/sl unknown
- 2015-01-12 US US15/111,000 patent/US9732095B2/en active Active
- 2015-01-12 RS RS20240415A patent/RS65437B1/sr unknown
- 2015-01-12 EA EA201691428A patent/EA031913B1/ru unknown
- 2015-01-12 MY MYPI2021007377A patent/MY197116A/en unknown
- 2015-01-12 JP JP2016563278A patent/JP6479850B2/ja active Active
2016
- 2016-07-03 IL IL246575A patent/IL246575B/en active IP Right Grant
- 2016-07-07 PH PH12016501344A patent/PH12016501344A1/en unknown
2017
- 2017-08-02 US US15/667,173 patent/US10047104B2/en active Active
2018
- 2018-08-03 US US16/054,512 patent/US10640517B2/en active Active
- 2018-11-20 AU AU2018267569A patent/AU2018267569B2/en active Active
- 2018-12-21 CY CY20181101382T patent/CY1121433T1/el unknown
2019
- 2019-02-06 JP JP2019019229A patent/JP6750053B2/ja active Active
- 2019-12-11 IL IL271364A patent/IL271364B/en unknown
- 2019-12-17 AU AU2019283795A patent/AU2019283795B2/en active Active
2020
- 2020-02-19 US US16/795,394 patent/US10995100B2/en active Active
- 2020-03-13 PH PH12020500529A patent/PH12020500529A1/en unknown
- 2020-06-25 JP JP2020109507A patent/JP6977111B2/ja active Active
- 2020-11-23 ZA ZA2020/07275A patent/ZA202007275B/en unknown
- 2020-11-23 ZA ZA2020/07273A patent/ZA202007273B/en unknown
- 2020-11-23 ZA ZA2020/07274A patent/ZA202007274B/en unknown
- 2020-11-23 ZA ZA2020/07276A patent/ZA202007276B/en unknown
2021
- 2021-01-19 HR HRP20210094TT patent/HRP20210094T1/hr unknown
- 2021-01-29 CY CY20211100076T patent/CY1123936T1/el unknown
- 2021-04-30 US US17/245,611 patent/US11691987B2/en active Active
- 2021-06-08 AU AU2021203761A patent/AU2021203761B2/en active Active
- 2021-11-10 JP JP2021183016A patent/JP7262553B2/ja active Active
2023
- 2023-04-11 JP JP2023063800A patent/JP7601937B2/ja active Active
- 2023-04-28 US US18/141,008 patent/US11981685B2/en active Active
- 2023-09-01 AU AU2023222987A patent/AU2023222987B2/en active Active
2024
- 2024-04-08 US US18/629,313 patent/US12410193B2/en active Active
- 2024-12-05 JP JP2024211949A patent/JP7775430B2/ja active Active
2025
- 2025-08-04 US US19/289,386 patent/US20250361244A1/en active Pending
- 2025-09-04 AU AU2025226775A patent/AU2025226775A1/en active Pending
- 2025-11-12 JP JP2025191819A patent/JP2026027431A/ja active Pending

Also Published As

Publication number	Publication date
AU2019283795B2 (en)	2021-04-01
HUE066261T2 (hu)	2024-07-28
JP7601937B2 (ja)	2024-12-17
US11691987B2 (en)	2023-07-04
PT3805233T (pt)	2024-04-15
SMT202400142T1 (it)	2024-05-14
KR20160115934A (ko)	2016-10-06
KR102392684B1 (ko)	2022-04-29
US20180370988A1 (en)	2018-12-27
AU2021203761A1 (en)	2021-07-08
PL3466955T3 (pl)	2021-06-28
US10047104B2 (en)	2018-08-14
PL3094329T3 (pl)	2019-03-29
DK3805233T3 (da)	2024-04-15
LT3094329T (lt)	2018-11-26
CN111362966A (zh)	2020-07-03
JP2019077729A (ja)	2019-05-23
EA201691428A1 (ru)	2016-12-30
EP3094329B1 (en)	2018-09-26
WO2015104688A1 (en)	2015-07-16
US20180022758A1 (en)	2018-01-25
FI3805233T3 (fi)	2024-04-17
EA201891917A1 (ru)	2019-02-28
RS61448B1 (sr)	2021-03-31
US10995100B2 (en)	2021-05-04
ZA202007273B (en)	2023-11-29
KR20230129622A (ko)	2023-09-08
HK1231410A1 (zh)	2017-12-22
SI3805233T1 (sl)	2024-07-31
JP6977111B2 (ja)	2021-12-08
IL246575B (en)	2019-12-31
EP4353324A2 (en)	2024-04-17
SG11201605486WA (en)	2016-08-30
SMT202100063T1 (it)	2021-03-15
BR112016016158B1 (pt)	2022-12-13
US10640517B2 (en)	2020-05-05
MX2016009013A (es)	2017-01-23
NZ722019A (en)	2022-07-01
IL246575A0 (en)	2016-08-31
RS65437B1 (sr)	2024-05-31
ZA202007274B (en)	2023-11-29
JP2017502088A (ja)	2017-01-19
EP3805233A1 (en)	2021-04-14
AU2025226775A1 (en)	2025-09-25
PH12016501344A1 (en)	2016-08-15
ZA202007275B (en)	2025-05-28
JP7262553B2 (ja)	2023-04-21
AU2015205374A1 (en)	2016-07-28
IL311677B1 (en)	2025-02-01
IL284952B (en)	2022-08-01
AU2018267569A1 (en)	2018-12-06
CU20160111A7 (es)	2017-03-03
AU2015205374B2 (en)	2018-08-23
IL302878A (en)	2023-07-01
SMT201800680T1 (it)	2019-01-11
KR20220061266A (ko)	2022-05-12
SG10201811204RA (en)	2019-01-30
IL271364A (en)	2020-01-30
KR20250049413A (ko)	2025-04-11
ES2846678T3 (es)	2021-07-28
KR102574390B1 (ko)	2023-09-04
LT3805233T (lt)	2024-05-10
CU24389B1 (es)	2019-04-04
JP2022024021A (ja)	2022-02-08
JP2020164546A (ja)	2020-10-08
CN106456619A (zh)	2017-02-22
US20200190112A1 (en)	2020-06-18
EP3466955B1 (en)	2020-12-16
US20230331740A1 (en)	2023-10-19
HUE041926T2 (hu)	2019-06-28
AU2019283795A1 (en)	2020-01-16
AU2023222987B2 (en)	2025-06-05
ES2692852T3 (es)	2018-12-05
PT3094329T (pt)	2018-11-26
US20220056046A1 (en)	2022-02-24
CN106456619B (zh)	2020-03-27
CY1121433T1 (el)	2020-05-29
SI3466955T1 (sl)	2021-05-31
TR201815683T4 (tr)	2018-11-21
HUE052252T2 (hu)	2021-04-28
JP2025032208A (ja)	2025-03-11
US9732095B2 (en)	2017-08-15
AU2018267569B2 (en)	2019-09-26
AU2023222987A1 (en)	2023-09-21
HRP20210094T1 (hr)	2021-03-05
AU2021203761B2 (en)	2023-06-01
IL284952A (en)	2021-08-31
IL294895B1 (en)	2023-06-01
IL317922A (en)	2025-02-01
IL302878B1 (en)	2024-05-01
SI3094329T1 (sl)	2019-02-28
IL271364B (en)	2021-08-31
RS58024B1 (sr)	2019-02-28
JP6750053B2 (ja)	2020-09-02
EP4353324A3 (en)	2024-07-03
EP3094329A1 (en)	2016-11-23
DK3466955T3 (da)	2021-02-01
ES2975436T3 (es)	2024-07-05
JP2026027431A (ja)	2026-02-18
EP3805233B1 (en)	2024-03-06
IL302878B2 (en)	2024-09-01
CA2935887A1 (en)	2015-07-16
IL311677B2 (en)	2025-06-01
EP3094329A4 (en)	2017-05-31
PH12020500529A1 (en)	2021-07-26
KR102785576B1 (ko)	2025-03-21
US20240294547A1 (en)	2024-09-05
IL294895B2 (en)	2023-10-01
ZA202007276B (en)	2025-05-28
EP3466955A1 (en)	2019-04-10
PT3466955T (pt)	2021-01-29
EA031913B1 (ru)	2019-03-29
BR112016016158A2 (pt)	2017-08-08
JP2023085526A (ja)	2023-06-20
MX359909B (es)	2018-10-16
JP6479850B2 (ja)	2019-03-06
DK3094329T3 (en)	2018-11-19
US12410193B2 (en)	2025-09-09
HRP20181795T1 (hr)	2019-01-25
CY1123936T1 (el)	2022-05-27
US20250361244A1 (en)	2025-11-27
JP7775430B2 (ja)	2025-11-25
MY197116A (en)	2023-05-26
NZ760657A (en)	2022-07-01
HRP20240489T1 (hr)	2024-07-05
CN111362966B (zh)	2022-03-11
PL3805233T3 (pl)	2024-06-10
US20160340366A1 (en)	2016-11-24
IL311677A (en)	2024-05-01
US11981685B2 (en)	2024-05-14
IL294895A (en)	2022-09-01
EA038748B1 (ru)	2021-10-14

Publication	Publication Date	Title
HUE052252T2 (hu)	2021-04-28	Eljárás IRAK4 inhibitorként rák kezelésére alkalmas oxazolo[4,5-b]piridin és tiazolo[4,5-b]piridin származékok elõállítására
LT3169328T (lt)	2022-06-10	Chinolino dariniai, skirti uždegiminių ligų gydymui
EP3240787A4 (en)	2018-06-20	Derivatives and methods of treating hepatitis b infections
LT3206497T (lt)	2021-02-25	Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui
LT3121175T (lt)	2020-03-10	1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai
EP3286311A4 (en)	2018-11-21	Method for the treatment of malignancies
HRP20180697T1 (hr)	2018-06-01	Spojevi imidazo[4,5-c]kinolin-2-ona i njihova upotreba za liječenje raka
LT3200815T (lt)	2021-07-26	Būdai ir kompozicijos, skirti vėžio gydymui
EP3294418A4 (en)	2019-01-02	Targeted selection of patients for treatment with cortistatin derivatives
EP3242947A4 (en)	2018-08-08	Method for the treatment of malignancies
HUE051448T2 (hu)	2021-03-01	Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
HUE051296T2 (hu)	2021-03-01	Benzoxazinon-származékok bõrbetegségek kezelésére
IL249502A0 (en)	2017-02-28	Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
HUE050974T2 (hu)	2021-01-28	Eljárás pirimidinszulfamid-származékok elõállítására
EP3180297A4 (en)	2018-01-17	Process for the manufacture of furural and furfural derivatives
HUE055463T2 (hu)	2021-11-29	Eljárás glükopiranozil-szubsztituált benzil-benzol-származékok elõállítására
EP3194377A4 (en)	2018-04-18	Heterocycle substituted amino-pyridine compounds and methods of use thereof
LT3601296T (lt)	2022-09-26	2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį
IL246721B (en)	2018-12-31	History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
EP3169405A4 (en)	2018-01-24	Methods, compounds, and compositions for the treatment of musculoskeletal diseases
LT3500572T (lt)	2023-02-10	Citizino dariniai, skirti priklausomybių gydymui
EP3100734A4 (en)	2017-08-09	Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma
EP3139911A4 (en)	2017-12-20	Method of treating advanced non-alcoholic steatohepatitis
EP3181562A4 (en)	2018-01-10	Phenylaminopyrimidine-derived compounds, method for producing the same, use of said compounds for the treatment of cancer, and treatment methods
HK1197910A (en)	2015-02-27	Substituted pyridine derivatives useful in the treatment of cancer